专利号:US-2020354404-A1 优先权日:2019-05-09 标 题 :Peptidomimetic agents, synthesis and uses thereof 发明人:AL-ABED YOUSEF 权利人:FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 摘要:Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.
专利号:US-4427827-A 优先权日:1982-10-20 标题 :Synthesis of hormone fragments 发明人:STEVENSON DAVID 权利人:USV PHARMA CORP 摘要:The yield of peptide synthesis processes of the type in which a protected intermediate resin peptide of the formula Resin--CH 2 --O--Phe--X, Resin--CH 2 --O--Gly--X, Resin--CH 2 --O--Ala--X, or Resin--CH 2 --O--Leu--X is deprotected, and successively protected amino acids are coupled to the resin peptide and deprotected, is increased significantly by deprotecting the first residue with trifluoroacetic acid and deprotecting the other residues with hydrogen chloride.
专利号:WO-0037615-A1 优先权日:1998-12-21 标 题 :Recombinant synthesis of beta-lipotropin and other peptides 发明人:HALE JOHN EDWARD; HERSHBERGER CHARLES LEE; LARSON JEFFREY LYNN; MENKE MICHAEL ANDREW 权利人:LILLY CO ELI; HALE JOHN EDWARD; HERSHBERGER CHARLES LEE; LARSON JEFFREY LYNN; MENKE MICHAEL ANDREW 摘要:The invention provides isolated nucleic acids, vectors, transformed host cells, fusion proteins, and recombinant methods for producing proteins using the propeptide sequence of procaboxypeptidase B.
专利号:US-12441760-B2 优先权日:2013-08-29 标 题 :Amino diacids containing peptide modifiers 发明人:BARLOS KLEOMENIS; GATOS DIMITRIOS; BARLOS KOSTAS K; VASILEIOU ZOI 权利人:CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S A 摘要:The present invention relates to peptide modifier compounds of Formula (1), or a salt thereof, wherein: a is an integer from 1 to 10, more preferably from 1 to 3; b is an integer from 0 to 7; Z is a terminal group and Y is a bivalent group. Further aspects of the invention relate to intermediates in the preparation of compounds of Formula (1), and the use of compounds of Formula (1) in the synthesis of peptide derivatives.
专利号:US-10125163-B2 优先权日:2015-10-23 标 题 :Solid phase peptide synthesis 发明人:COLLINS JONATHAN M 权利人:CEM CORP 摘要:An improved method of deprotection in solid phase peptide synthesis is disclosed. In particular the deprotecting composition is added in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated acid from the preceding coupling cycle, and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle. Thereafter, the ambient pressure in the vessel is reduced with a vacuum pull to remove the deprotecting composition without any draining step and without otherwise adversely affecting the remaining materials in the vessel or causing problems in subsequent steps in the SPPS cycle.
专利号:US-2006165683-A1 优先权日:2001-12-05 标题:Methods and compositions for control of bone formation via modulation of sympathetic tone 发明人:KARSENTY GERARD; TAKEDA SHU; ELEFTERIOU FLORENT 权利人:KARSENTY GERARD; TAKEDA SHU; ELEFTERIOU FLORENT 摘要:This invention relates to methods for treatment, diagnosis and prevention of bone disease and comprises methods including measurement and modulation of sympathetic tone and leptin activity. Alteration of sympathetic tone in bone disease can be accomplished by decreasing or increasing leptin synthesis, leptin receptor synthesis, leptin binding to the leptin receptor, and leptin receptor activity. Alteration of sympathetic tone in bone disease can also be accomplished in the foregoing manner, in combination with traditional sympathetic nervous system agonists and/or antagonists, such as, but not limited to, a dopamine β hydroxylase antagonist or a β adrenergic antagonist for treatment or prevention of osteoporosis.
1: Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA- Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. 2: Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024 Sep 23;19(1):89. doi: 10.1007/s11657-024-01447-7. Erratum in: Arch Osteoporos. 2024 Nov 21;19(1):118. doi: 10.1007/s11657-024-01478-0. 3: Wen MT, Li JC, Lu BW, Shao HR, Ling PX, Liu F, Li G, Luo D. Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS). Front Pharmacol. 2024 Aug 7;15:1391356. doi: 10.3389/fphar.2024.1391356.
合成参考文献
参考文献:10.1210/jc.2011-0593 摘要:Carvalho NNC, Voss LA, Almeida MOP, Salgado CL, Bandeira F. Atypical Femoral Fractures during Prolonged Use of Bisphosphonates: Short-Term Responses to Strontium Ranelate and Teriparatide. The Journal of Clinical Endocrinology & Metabolism. 2011 Sep;96(9):2675–80. doi: 10.1210/jc.2011-0593. 参考文献:10.1007/s00198-011-1730-y 摘要:Tseng Y-, Su C-, Lui T-, Yeh Y-, Yeh S-. Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. Osteoporosis International. 2011 Jul 19;23(5):1613–22. doi: 10.1007/s00198-011-1730-y. 参考文献:10.1007/s00198-011-1725-8 摘要:Wong M, Wan X, Ruff V, Krohn K, Taylor K. Gender differences for initiating teriparatide therapy: baseline data from the Direct Assessment of Nonvertebral Fracture in the Community Experience (DANCE) study. Osteoporos Int. 2012 Apr;23(4):1445–52. doi: 10.1007/s00198-011-1725-8. 摘要:Marumo K, Saito M. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis]. Nihon Rinsho. 2011 Jul;69(7):1264–9. 参考文献:10.4081/reumatismo.2011.67 摘要:Di Munno O, Delle Sedie A. [Prevention and treatment of glucocorticoid-induced osteoporosis in International and Italian scenarios]. Reumatismo. 2011;63(2):67–79. doi: 10.4081/reumatismo.2011.67.